%0 Journal Article
%T Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types
%A Alona Zilberberg
%A Chaim Wachtel
%A Danny Barash
%A Helit Cohen
%A Iris Barshack
%A Jacob Korach
%A Keren Bahar-Shany
%A Keren Levanon
%A Rotem Ben-Hamo
%A Sarit Aviel-Ronen
%A Sol Efroni
%J Archive of "NPJ Precision Oncology".
%D 2019
%R 10.1038/s41698-019-0084-3
%X Eleven SNPs were identified within TUBB1 and BCL2. a In OV, two SNPs (rs6070697, rs1801018) present a frequency that may be of use for the stratification of patients according to their response status. b rs6070697 is of the same frequency in both groups (t test p-value£¿<£¿0.96). A study of the polymorphisms of TUBB1 and BCL2 in UCEC shows similar results (c) for all polymorphism, while a more careful study (d) of rs6070697 again demonstrates that it does not present a significant difference in the two response groups (t test p-value£¿<£¿0.19), and a study of HNSC follows these (t test p-value£¿<£¿0.25) findings (e, f), as does a validation set composed of data from all TCGA patients that were treated with a first line of paclitaxel (excluding OV, UCEC, and HSNC) of other types of cancer. This validation set includes sequence data from 86 patients with BLCA, CESC, ESCA, LUAD, LUSC, SKCM, STAD, UCS. Similar to OV, UCEC and HNSC, this combined set does not present any polymorphism with significant association to response (g), including the candidate rs6070697 (t test p-value£¿<£¿0.13) (h
%K High-throughput screening
%K Cancer genomics
%K Molecular biology
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478919/